Life sciences firm Promentis Pharmaceuticals raises $2.9m to develop drugs targeting schizophrenia and other central nervous system disorders.
Promentis Pharmaceuticals, a spin-out from the universities of Marquette and Wisconsin-Milwaukee, has secured $2.9m in funding. Germany-based investment firm Black Horse Investments led the round, which was joined by angel network Golden Angels Investors and private investors. The Milwaukee-based firm previously held a series A round, led by Golden Angels, which was worth $1.94m. It…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
